Consequently, scholars have proposed alternative biomarkers, including free PSA, prostate-specific membrane antigen, prostate cancer antigen 3, human kallikerin 2, and others, to enhance the accuracy of prostate cancer diagnosis and mitigate the issues of excessive diagnosis and treatment [31]. This evidence concerns the gene KLK3 and prostate carcinoma.